T. Rowe Price Associates
EPIX

T. Rowe Price Associates’s ESSA Pharma EPIX Stock Holding History

T. Rowe Price Associates’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-44,832
Closed -$82K – 2946
2022
Q3 		$82K Sell
44,832
-74,619
-62% -$197K ﹤0.01% 2768
2022
Q2 		$376K Hold
119,451
– – ﹤0.01% 2340
2022
Q1 		$738K Buy
+119,451
New +$1.05M ﹤0.01% 2165
2021
Q4 		– Sell
-24,303
Closed -$194K – 2999
2021
Q3 		$194K Hold
24,303
– – ﹤0.01% 2735
2021
Q2 		$694K Buy
+24,303
New +$706K ﹤0.01% 2224

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

T. Rowe Price Associates's EPIX Position: Q4 2022 in Review

T. Rowe Price Associates sold out of ESSA Pharma (EPIX) in Q4 2022, closing a stake of 44,832 shares — an estimated $82K sold.

T. Rowe Price Associates first reported a position in EPIX in Q2 2021 and held it in 5 quarters. The position peaked at $738K in Q1 2022. 45 funds tracked by Wall St. Rank hold EPIX as of Q4 2022.

  • T. Rowe Price Associates reported no remaining ESSA Pharma position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 44,832 ESSA Pharma shares in Q4 2022, an estimated $82K.
  • T. Rowe Price Associates first reported a position in ESSA Pharma in Q2 2021 and held it in 5 quarters.
  • T. Rowe Price Associates's ESSA Pharma position peaked at $738K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.